[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Lin HF, Lui CC, Hsu HC, Lin SA: Orbital exenteration for secondary orbital tumors: a series of seven cases. Chang Gung Med J; 2002 Sep;25(9):599-605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital exenteration for secondary orbital tumors: a series of seven cases.
  • BACKGROUND: Exenteration is indicated in patients with malignant neoplasms of orbital contents.
  • It entails the removal of the eyeball together with its extraocular muscles and other soft tissues.
  • Primary lesions, histopathological examination results, treatments, and recurrences are discussed.
  • Two patients underwent total exenteration without socket augmentation; 4 patients underwent exenteration/ subtotal exenteration with immediate facial reconstruction, and 1 with delayed facial reconstruction.
  • Radiotherapy was performed in 6 of the patients and chemotherapy in 2.
  • Central nerve system invasion was noted in 2 patients, and 1 died due to it.
  • CONCLUSION: Secondary orbital tumors involved the orbit from adjacent tissues: paranasal sinuses, nasopharynx, lacrimal sac, conjunctiva, eyelid, intraocular tissue, and intracranial tissues.
  • Combined surgeries are necessary for complete tumor removal.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Orbit Evisceration / methods. Orbital Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479621.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


2. Fujiwara K, Uenohara H, Suzuki H, Sakurai Y: Intracranial germinoma with syncytiotrophoblastic giant cells in the cerebellopontine angle--case report. Neurol Med Chir (Tokyo); 2002 Mar;42(3):132-6
Genetic Alliance. consumer health - Germinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 23-year-old man presented with a 3-week history of left hearing disturbance and left facial nerve paresis.
  • Gross total removal of the tumor was achieved.
  • Histological examination revealed that the tumor was a germinoma with syncytiotrophoblastic giant cells.
  • Whole central nervous system irradiation with cisplatin-etoposide chemotherapy was performed postoperatively.
  • Intracranial germ cell tumors in the CPA are very rare.
  • Total surgical removal followed by irradiation and chemotherapy will provide a good outcome.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Cerebellopontine Angle / surgery. Germinoma / surgery. Giant Cells
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy. Humans. Male. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11936056.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. König M, Mork J, Hall KS, Osnes T, Meling TR: Multimodal treatment of osteogenic sarcoma of the jaw. Skull Base; 2010 May;20(3):207-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment of osteogenic sarcoma of the jaw.
  • Osteosarcomas (OSs) account for 40 to 60% of primary malignant bone tumors.
  • We treated a 30-year-old patient with 26-month history of right-sided facial pain and paresthesia.
  • Investigation showed high-grade OS of the right mandibular coronoid process, affecting the mandibular nerve, middle cranial fossa, internal jugular vein, and internal carotid artery (ICA).
  • True en bloc resection was performed after upfront adjuvant chemotherapy.
  • The ICA was trap-ligated intradurally, whereafter the floor of the middle fossa, including the mandibular nerve and the glenoid fossa, was detached from the skull base in one piece.
  • Subsequently, a hemimandibulectomy, total parotidectomy, ICA sacrifice, and removal of the pterygoid plates and muscles were performed, and the abovementioned structures were removed as a solitary specimen, including the facial nerve branches overlying the tumor.
  • A sural nerve graft was interposed between five major facial nerve branches to reanimate the face.
  • The patient had an uneventful recovery, is able to eat, and has a partial facial nerve palsy.
  • He has no tumor recurrence 26 months after surgery.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2008 Oct;63(4):651-60; dicussion 660-1 [18824944.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Oct;72(4):444-8 [1923444.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Sep;64(3):302-7 [2443891.001]
  • [Cites] J Neurosurg. 1985 May;62(5):667-72 [3989589.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):56-61 [9001266.001]
  • [Cites] Oral Oncol. 2001 Oct;37(7):545-7 [11564573.001]
  • [Cites] Laryngoscope. 1999 Jun;109(6):964-9 [10369291.001]
  • [Cites] Am J Surg. 1980 Oct;140(4):572-6 [6932821.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):374-6 [7719220.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Jun;26(3):191-7 [9180229.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Jun;26(3):198-204 [9180230.001]
  • [Cites] Head Neck. 1997 Sep;19(6):513-23 [9278760.001]
  • [Cites] J Otolaryngol. 2004 Jun;33(3):139-44 [15841989.001]
  • [Cites] Oral Oncol. 2008 Mar;44(3):286-94 [17467326.001]
  • [Cites] Head Neck. 2008 Aug;30(8):1020-6 [18383528.001]
  • (PMID = 21318040.001).
  • [ISSN] 1532-0065
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3037111
  • [Keywords] NOTNLM ; Osteosarcoma / craniofacial surgery / en bloc resection / jaw tumor / tumor of the skull base
  •  go-up   go-down


Advertisement
4. Damascelli B, Patelli GL, Lanocita R, Di Tolla G, Frigerio LF, Marchianò A, Garbagnati F, Spreafico C, Tichà V, Gladin CR, Palazzi M, Crippa F, Oldini C, Calò S, Bonaccorsi A, Mattavelli F, Costa L, Mariani L, Cantù G: A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol; 2003 Jul;181(1):253-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings.
  • OBJECTIVE: The purpose of our study was to evaluate the effectiveness of intraarterial infusion of paclitaxel incorporated into human albumin nanoparticles for use as induction chemotherapy before definitive treatment of advanced squamous cell carcinoma of the tongue.
  • SUBJECTS AND METHODS: Twenty-three previously untreated patients (age range, 27-75 years) who had carcinoma of the tongue (stage T3-T4, any N) received intraarterial therapy with paclitaxel incorporated into albumin nanoparticles delivered by transfemoral catheterization into the external carotid artery (10 patients), selectively into the lingual artery (12 patients), or into a faciolingual trunk (1 patient).
  • Of these 16 patients, eight subsequently received radiotherapy, and three received a combination of chemotherapy and radiotherapy.
  • Of the remaining seven patients, one received chemotherapy alone, four received radiotherapy alone, one received chemotherapy plus radiotherapy, and one refused any further treatment.
  • The toxicities encountered were hematologic (grade 3) in two patients (8.6%) and neurologic (grade 4) in two patients (reversible paralysis of the facial nerve, 8.6%).
  • CONCLUSION: Intraarterial infusion of paclitaxel in albumin nanoparticles proved reproducible and effective and deserves further investigation as induction chemotherapy before definitive treatment of advanced tumors of the tongue, with a view to organ preservation.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Infusions, Intra-Arterial. Paclitaxel / administration & dosage. Tongue Neoplasms / drug therapy
  • [MeSH-minor] Drug Delivery Systems. Female. Humans. Male. Middle Aged. Particle Size. Serum Albumin / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12818869.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Serum Albumin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Bouyon A, Hans S, Durdux C, Housset M: [Postoperative treatment of malignant tumors of the parotid gland: radiotherapy, concomitant chemotherapy and radiation therapy?]. Cancer Radiother; 2007 Dec;11(8):465-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative treatment of malignant tumors of the parotid gland: radiotherapy, concomitant chemotherapy and radiation therapy?].
  • The low incidence, the wide histological spectrum and the natural, sometimes slow, evolution of malignant parotid gland tumours do not allow to easily establish the impact of their treatments.
  • We present here the therapeutic highlights of parotid cancers: surgery, with the particular concern of facial nerve preservation; and adjuvant treatment essentially based on radiotherapy.
  • This review focused on adjuvant care explores the indications and the technical aspects of radiation, as well as the role of concurrent chemotherapy.
  • [MeSH-major] Parotid Neoplasms / radiotherapy. Parotid Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy / methods. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17888707.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Prigent M, Teissier N, Peuchmaur M, El Maleh-Berges M, Philippe-Chomette P, Cardin P, Orbach D: Sialoblastoma of salivary glands in children: chemotherapy should be discussed as an alternative to mutilating surgery. Int J Pediatr Otorhinolaryngol; 2010 Aug;74(8):942-5
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sialoblastoma of salivary glands in children: chemotherapy should be discussed as an alternative to mutilating surgery.
  • Sialoblastoma is a very rare congenital salivary gland tumor.
  • No consensus has been reached concerning the treatment of this tumor due to its rarity.
  • The treatment of reference is surgery, which can be mutilating, in the case of a locally invasive tumor.
  • The treatment of metastatic disease is also controversial.
  • The first cytological diagnosis was that of pleomorphic adenoma.
  • Due to local progression, superficial parotidectomy was performed at the age of 3.5 years and revealed a diagnosis of sialoblastoma.
  • Six months later, local recurrence and lung metastasis were treated by neoadjuvant chemotherapy with a very good partial response on the local recurrence and the lung metastasis, allowing complete parotidectomy with sacrifice of the facial nerve.
  • Bilateral lung biopsies after adjuvant chemotherapy showed total necrosis.
  • This case and a review of the literature confirm the very good chemosensitivity of this tumor and argue in favor of neoadjuvant chemotherapy for locally invasive tumors rather than extensive mutilating surgery.
  • [MeSH-major] Adenoma, Pleomorphic / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Biopsy, Needle. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neoplasm Staging. Rare Diseases. Risk Assessment. Salivary Glands / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright (c) 2010. Published by Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20554035.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


7. Héran F, Williams M, Ayache D: [MRI of the temporal bone]. J Radiol; 2006 Nov;87(11 Pt 2):1783-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors and malignant otitis externa are the most common lesions of the external auditory canal.
  • The diagnosis of petrous apex abnormalities is emphasized: cholesterol granuloma, malignant tumor, epidermoid cyst, cholesteatoma, and petrositis.
  • This study also includes the main aspects of facial nerve lesions and vascular abnormalities of the area on MRI.
  • [MeSH-major] Cholesteatoma, Middle Ear / diagnosis. Fibrous Dysplasia of Bone / diagnosis. Labyrinthitis / diagnosis. Magnetic Resonance Imaging. Neuroma, Acoustic / diagnosis. Otitis Externa / diagnosis. Skull Neoplasms / diagnosis. Temporal Bone
  • [MeSH-minor] Anticoagulants / therapeutic use. Cholesterol. Diagnosis, Differential. Epidermal Cyst / diagnosis. Follow-Up Studies. Granuloma, Foreign-Body / diagnosis. Hematoma / drug therapy. Hematoma / etiology. Humans. Male. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Middle Aged. Petrous Bone. Postoperative Complications. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124479.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticoagulants; 97C5T2UQ7J / Cholesterol
  • [Number-of-references] 30
  •  go-up   go-down


8. Stillman M, Cata JP: Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep; 2006 Aug;10(4):279-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of chemotherapy-induced peripheral neuropathy.
  • Recent advances in the development and administration of chemotherapy for malignant diseases have been rewarded with prolonged survival rates.
  • The cost of progress has come at a price and the nervous system is frequently the target of chemotherapy-induced neurotoxicity.
  • Unlike more immediate toxicities that effect the gastrointestinal tract and bone marrow, chemotherapy-induced neurotoxicity is frequently delayed in onset and may progress over time.
  • In the peripheral nervous system, the major brunt of the toxicity is directed against the peripheral nerve, resulting in chemotherapy-induced peripheral neuropathy (CIPN).
  • Chemotherapeutic agents used to treat hematologic and solid tumors target a variety of structures and functions in the peripheral nervous system, including the neuronal cell body, the axonal transport system, the myelin sheath, and glial support structures.
  • Combined with the call for a greater recognition of the potentially devastating ramifications of CIPN on quality of life, basic and clinical researchers have begun to investigate therapy to prevent neurotoxic injury.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Peripheral Nervous System Diseases / chemically induced. Peripheral Nervous System Diseases / therapy
  • [MeSH-minor] Disease Management. Humans. Neoplasms / drug therapy. Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Jun;17(4):271-6 [15997923.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1746-50 [16039110.001]
  • [Cites] Neurology. 1995 Oct;45(10):1848-55 [7477980.001]
  • [Cites] Ann Oncol. 2000 May;11(5):509-13 [10907941.001]
  • [Cites] Curr Oncol Rep. 2005 May;7(3):159-60 [15847705.001]
  • [Cites] N Engl J Med. 1990 Jan 11;322(2):89-94 [2152972.001]
  • [Cites] Ann Neurol. 1994 Mar;35(3):304-11 [7907208.001]
  • [Cites] Semin Neurol. 2005 Jun;25(2):204-16 [15937736.001]
  • [Cites] Neurology. 1999 Nov 10;53(8):1634-40 [10563605.001]
  • [Cites] Br J Cancer. 1997;75(3):417-22 [9020489.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):916-7 [8625200.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):461-7 [14760066.001]
  • [Cites] Neurology. 1996 Jan;46(1):108-11 [8559355.001]
  • [Cites] Neurosci Lett. 2005 Sep 23;386(1):18-22 [15975716.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61 [15217938.001]
  • [Cites] Cancer Invest. 2004;22(3):471-3 [15493367.001]
  • [Cites] Neurology. 2003 Jan 28;60(2):337-40 [12552058.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3478-83 [12177109.001]
  • [Cites] J Neurooncol. 1997 Oct;35(1):47-53 [9266440.001]
  • [Cites] Pain. 2004 May;109(1-2):132-42 [15082135.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):739-44 [9739440.001]
  • [Cites] Neuroscience. 2006;138(1):329-38 [16361064.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1356-62 [8608515.001]
  • [Cites] BMC Cancer. 2006 Jan 07;6:5 [16398939.001]
  • [Cites] Arch Neurol. 2003 Nov;60(11):1524-34 [14623723.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1691-3 [15755989.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):927-31 [12610195.001]
  • [Cites] Brain. 1996 Dec;119 ( Pt 6):2039-52 [9010008.001]
  • [Cites] Neurology. 2005 Jan 11;64(1):26-31 [15642899.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):1872-5 [12499476.001]
  • [Cites] Support Care Cancer. 2005 Aug;13(8):647-51 [15711945.001]
  • [Cites] Minerva Anestesiol. 2006 Mar;72(3):151-69 [16493391.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4843-50 [16000582.001]
  • [Cites] Anticancer Drugs. 2005 Jun;16(5):587-91 [15846125.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):935-40 [8622042.001]
  • [Cites] Eur J Cancer. 2005 May;41(8):1135-9 [15911236.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1890-8 [15756015.001]
  • [Cites] Neurology. 2003 Nov 11;61(9):1297-300 [14610145.001]
  • [Cites] Neurology. 1989 Mar;39(3):368-73 [2564647.001]
  • [Cites] Muscle Nerve. 2004 Mar;29(3):387-92 [14981738.001]
  • [Cites] Neurosci Lett. 2006 Apr 24;397(3):219-23 [16406309.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1685-6 [15755987.001]
  • [Cites] Lancet. 2003 Jun 21;361(9375):2099-106 [12826431.001]
  • [Cites] Neurol Clin. 2003 Feb;21(1):279-318, x [12690653.001]
  • [Cites] J Neurol. 1994 Jun;241(7):432-5 [7931444.001]
  • [Cites] Neuroscience. 2006;138(4):1351-60 [16426766.001]
  • [Cites] Muscle Nerve. 2005 Jul;32(1):51-60 [15880395.001]
  • (PMID = 16834943.001).
  • [ISSN] 1531-3433
  • [Journal-full-title] Current pain and headache reports
  • [ISO-abbreviation] Curr Pain Headache Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


9. Selesnick SH, Burt BM: Regional spread of nonneurogenic tumors to the skull base via the facial nerve. Otol Neurotol; 2003 Mar;24(2):326-33
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional spread of nonneurogenic tumors to the skull base via the facial nerve.
  • OBJECTIVE: This study examined the clinical and pathologic features of regional spread of nonneurogenic neoplastic disease to the intratemporal segments of the facial nerve.
  • PATIENTS: Six patients with neoplastic disease of nonneurogenic origin involving segments of the facial nerve within the temporal bone.
  • Five patients received adjuvant radiation, and two received adjuvant radiation and chemotherapy.
  • MAIN OUTCOME MEASURES: Histopathology, site of primary tumor, intratemporal location of regional spread along the facial nerve, degree of facial paralysis, and presence of residual disease.
  • In addition, one case of benign pleomorphic adenoma of the parotid gland that circumferentially involved an intratemporal segment of the facial nerve was reported.
  • Facial paralysis was present in five of six (83%) of cases.
  • Four patients had unresectable malignant disease, and two died despite multimodality therapy.
  • CONCLUSIONS: The facial nerve provides a route for the spread of neoplastic disease into the temporal bone, and perineural invasion is an important mechanism of invasion and motility of malignant disease.
  • Nonneurogenic intratemporal tumors of the facial nerve are a rare but significant cause of facial paralysis.
  • [MeSH-major] Carcinoma / pathology. Cranial Nerve Neoplasms / pathology. Facial Nerve / pathology. Parotid Neoplasms / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Child. Female. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Radiopharmaceuticals. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621352.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


10. Harish K: Management of primary malignant epithelial parotid tumors. Surg Oncol; 2004 Jul;13(1):7-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary malignant epithelial parotid tumors.
  • These tumors carry a prolonged risk of recurrence and metastasis.
  • Controversies surrounding pre-treatment evaluation by imaging and fine needle aspiration, utility of operative frozen section are partly resolved.
  • Though surgery remains the mainstay of treatment, radiation is being recognized as a useful adjuvant.
  • Facial nerve preservation is one of the important goals at surgery.
  • The role of chemotherapy is still investigational.
  • The prognosis and necessity of elective neck treatment are mainly guided by the tumor grade and stage.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / therapy. Parotid Neoplasms / therapy
  • [MeSH-minor] Humans. Lymph Node Excision. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15145029.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 81
  •  go-up   go-down


11. Scianna JM, Petruzzelli GJ: Contemporary management of tumors of the salivary glands. Curr Oncol Rep; 2007 Mar;9(2):134-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary management of tumors of the salivary glands.
  • Management of tumors of the salivary glands requires a detailed understanding of the anatomy and pathologic processes affecting these glands.
  • Salivary glands give rise to benign and malignant neoplasms and are affected by a variety of systemic diseases.
  • Surgical extirpation is the primary modality for management of tumors of the salivary glands.
  • Parotid surgery carries a potentially high morbidity with possible unsightly scarring and facial nerve damage.
  • Nontraditional surgical approaches and instrumentation, as well as facial nerve monitoring, can decrease the morbidity of a parotidectomy.
  • In specific instances, malignant salivary gland tumors warrant cervical lymphadenectomy.
  • Adjuvant therapy is primarily accomplished with radiation.
  • Chemotherapy continues to play a palliative role in salivary gland malignancies; however, newer trials are investigating the therapeutic role of chemotherapy.
  • [MeSH-major] Salivary Gland Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 May;109(5):754-62 [10334226.001]
  • [Cites] Laryngoscope. 2004 May;114(5):949-56 [15126763.001]
  • [Cites] ANZ J Surg. 2003 Sep;73(9):692-6 [12956783.001]
  • [Cites] Ear Nose Throat J. 2005 Sep;84(9):597-602 [16261761.001]
  • [Cites] Tumori. 2001 Jan-Feb;87(1):14-7 [11669550.001]
  • [Cites] ANZ J Surg. 2001 Dec;71(12):753-6 [11906393.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1299-303 [12897549.001]
  • [Cites] Laryngoscope. 2005 Feb;115(2):331-6 [15689761.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] ANZ J Surg. 2005 Mar;75(3):144-6 [15777394.001]
  • [Cites] Radiology. 2005 Nov;237(2):563-9 [16244265.001]
  • [Cites] Laryngoscope. 2001 Sep;111(9):1533-44 [11568602.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Feb;130(2):187-9 [14967748.001]
  • [Cites] Br J Radiol. 2006 Apr;79(940):295-7 [16585720.001]
  • [Cites] Radiother Oncol. 2001 Aug;60(2):163-72 [11439211.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):169-77 [11325446.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Apr;132(4):375-80 [16618905.001]
  • [Cites] Br J Radiol. 2005 Apr;78(928):362-9 [15774602.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):161-7 [11325445.001]
  • [Cites] Acta Otolaryngol. 2002 Sep;122(6):673-8 [12403133.001]
  • [Cites] J Ultrasound Med. 2005 Jan;24(1):77-86 [15615931.001]
  • [Cites] Br J Radiol. 2004 Jul;77(919):600-6 [15238408.001]
  • [Cites] Br J Radiol. 2005 Jul;78(931):642-5 [15961849.001]
  • [Cites] Laryngoscope. 2005 Jul;115(7):1310-4 [15995527.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2003 Oct;23(5):368-76 [15108487.001]
  • [Cites] Anticancer Drugs. 2002 Jun;13(5):491-5 [12045460.001]
  • [Cites] Laryngoscope. 2005 Sep;115(9):1624-6 [16148706.001]
  • [Cites] J Ultrasound Med. 2004 Jun;23 (6):777-83 [15244301.001]
  • [Cites] Clin Adv Hematol Oncol. 2003 Apr;1(4):226-8 [16224411.001]
  • [Cites] Laryngoscope. 2004 Sep;114(9):1652-5 [15475799.001]
  • [Cites] Ear Nose Throat J. 2004 Feb;83(2):128-31 [15008447.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1070-3 [15933523.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):541-7 [11169936.001]
  • [Cites] ANZ J Surg. 2004 Jul;74(7):563-8 [15230791.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3781-3 [11268454.001]
  • [Cites] Aesthetic Plast Surg. 2006 Jan-Feb;30(1):125-31 [16402160.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Oct;123(10):1091-6 [9339986.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):1070-5 [12782825.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):849-56 [15262762.001]
  • [Cites] ANZ J Surg. 2005 Nov;75(11):948-52 [16336383.001]
  • (PMID = 17288880.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


12. Minovi A, Basten O, Hunter B, Draf W, Bockmühl U: Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review. Head Neck; 2007 May;29(5):439-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review.
  • BACKGROUND: This study analyzes the management and outcomes of a series of 10 malignant peripheral nerve sheath tumors (MPNST) of the head and neck.
  • METHODS: From 1984 to 2004, 10 patients underwent surgical treatment of a MPNST.
  • RESULTS: Eight tumors were located at the lateral skull base; 2 involved the vagus nerve in isolation.
  • Seventy percent of the tumors could be resected completely.
  • Negative prognostic indicators were advanced tumor stage, early recurrence, and presumably also the presence of von Recklinghausen's disease.
  • CONCLUSIONS: Although rare, MPNST is one of the most aggressive tumors in the head and neck area.
  • Complete tumor removal is the mainstay of treatment and most important prognostic factor of MPNST.
  • The role of adjuvant chemotherapy remains controversial.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 17163467.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


13. Quiñones-Hinojosa A, Friedlander RM, Boyer PJ, Batchelor TT, Chiocca EA: Solitary sciatic nerve lymphoma as an initial manifestation of diffuse neurolymphomatosis. Case report and review of the literature. J Neurosurg; 2000 Jan;92(1):165-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary sciatic nerve lymphoma as an initial manifestation of diffuse neurolymphomatosis. Case report and review of the literature.
  • Solitary peripheral nerve lymphomas are exceedingly rare primary manifestations of diffuse peripheral nervous system or central nervous system (CNS) lymphomatosis.
  • Magnetic resonance imaging studies revealed a solitary fusiform tumor, extending from the sciatic nerve, at the level of the lesser trochanter of the femur, into the posterior tibial nerve below the popliteal fossa.
  • Intraoperative gross examination found that the tumor diffusely expanded the nerve, but did not extend from or into surrounding muscle or tendons.
  • The final histological diagnosis was a solitary extranodal lymphoma (Burkittlike high-grade B-cell lymphoma).
  • Four months after the surgical biopsy, the patient presented with a right facial nerve palsy.
  • The patient underwent intrathecal chemotherapy followed by systemic myelosuppressive chemotherapy with bone marrow rescue, but died of respiratory failure while still receiving treatment.
  • Postmortem examination revealed extensive lymphomatosis in the peripheral nerves and spinal nerve roots without evidence of cranial nerve, CNS, or other organ system involvement.
  • The aggressive biological characteristics of these tumors, their management, and pertinent literature are reviewed.
  • [MeSH-major] Lymphoma / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Sciatic Nerve
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10616097.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 20
  •  go-up   go-down


14. Gosau M, Draenert FG, Müller S, Frerich B, Bürgers R, Reichert TE, Driemel O: Two modifications in the treatment of keratocystic odontogenic tumors (KCOT) and the use of Carnoy's solution (CS)--a retrospective study lasting between 2 and 10 years. Clin Oral Investig; 2010 Feb;14(1):27-34
Hazardous Substances Data Bank. CHLOROFORM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two modifications in the treatment of keratocystic odontogenic tumors (KCOT) and the use of Carnoy's solution (CS)--a retrospective study lasting between 2 and 10 years.
  • This retrospective study aimed at evaluating the recurrence rates of keratocystic odontogenic tumors (KCOTs) that were enucleated with and without the application of Carnoy's solution (CS).
  • Recurrence rates were investigated in correlation with the respective treatment method applied.
  • Additionally, any damage to the inferior alveolar nerve associated with treatment was analyzed.
  • Treatments consisted of enucleation with (38.9%) or without (61.1%) the application of CS.
  • No detrimental effects of CS on the mandibular nerve were detected.
  • The application of CS did not cause any damage to the mandibular nerve.
  • [MeSH-major] Acetic Acid / therapeutic use. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Chloroform / therapeutic use. Ethanol / therapeutic use. Jaw Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control. Odontogenic Tumors / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cautery / methods. Child. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Mandibular Nerve / drug effects. Middle Aged. Neovascularization, Pathologic / drug therapy. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. ACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Oral Investig. 2010 Dec;14(6):719-21 [20838833.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):202-6 [8762878.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Jan;36(1):20-5 [17156974.001]
  • [Cites] J Oral Maxillofac Surg. 1985 Mar;43(3):177-82 [2579223.001]
  • [Cites] Hum Genet. 1997 Oct;100(5-6):497-502 [9341860.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jun;52(6):599-606 [8189298.001]
  • [Cites] Br J Oral Maxillofac Surg. 1997 Feb;35(1):46-8 [9043004.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] J Can Dent Assoc. 2008 Mar;74(2):165-165h [18353202.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Nov;90(5):553-8 [11077375.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Jun;62(6):651-5; discussion 655-6 [15170272.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Jan;50(1):22-6 [1370082.001]
  • [Cites] J Oral Maxillofac Surg. 2005 May;63(5):635-9 [15883937.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Sep;72(3):265-9 [1717918.001]
  • [Cites] Mund Kiefer Gesichtschir. 2007 Sep;11(4):221-31 [17641919.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Mar;64(3):379-83 [16487797.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Sep;52(9):960-3 [8064460.001]
  • [Cites] J Dent Res. 1999 Jul;78(7):1345-53 [10403462.001]
  • [Cites] Int J Oral Maxillofac Surg. 1988 Feb;17(1):25-8 [3127485.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Nov;63(11):1662-6 [16243184.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Sep;52(9):964-6 [8064461.001]
  • [Cites] J Oral Sci. 2007 Sep;49(3):229-35 [17928730.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jan;101(1):5-9; discussion 10 [16360602.001]
  • [Cites] J Oral Maxillofac Surg. 2001 Jul;59(7):720-5; discussion 726-7 [11429726.001]
  • [Cites] Med Oral. 2001 Nov-Dec;6(5):350-7 [11694868.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Aug;94(2):151-6 [12221380.001]
  • [Cites] Dtsch Zahnarztl Z. 1991 Jan;46(1):80-3 [1725863.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Nov;94(5):543-53 [12424446.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Nov;86(5):573-7 [9830650.001]
  • [Cites] Oral Maxillofac Surg Clin North Am. 2003 Aug;15(3):317-24 [18088685.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jul;86(1):42-7 [9690244.001]
  • [Cites] Int J Oral Maxillofac Surg. 2001 Feb;30(1):14-25 [11289615.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1990 Sep-Oct;14(5):375-7 [2135243.001]
  • [Cites] J Maxillofac Surg. 1981 Nov;9(4):228-36 [6172530.001]
  • [Cites] J Oral Maxillofac Surg. 1984 Jan;42(1):10-9 [6199488.001]
  • [Cites] J Dent Res. 2000 Jun;79(6):1418-22 [10890722.001]
  • (PMID = 19294436.001).
  • [ISSN] 1436-3771
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carnoy's solution; 3K9958V90M / Ethanol; 7V31YC746X / Chloroform; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


15. Kurian S, Ertan E, Ducatman B, Crowell EB, Rassekh C: Esthesioneuroblastoma in Maffucci's syndrome. Skeletal Radiol; 2004 Oct;33(10):609-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 33-year-old man with Maffucci's syndrome who presented with a several month history of nasal congestion, facial pain, and diminished vision in his left eye.
  • Radiological studies showed a large soft tissue mass centered in the sinonasal area, extending bilaterally into maxillary sinuses and orbits with compression of left optic nerve.
  • Chemotherapy resulted in initial improvement, but the tumor recurred and did not respond to further treatment, resulting in his death.
  • Sarcomatous tumors are reported in Maffucci's syndrome, but this is a rare case of a neuroendocrine tumor in a patient with Maffucci's syndrome.
  • [MeSH-major] Enchondromatosis / complications. Esthesioneuroblastoma, Olfactory / diagnosis. Nasal Cavity / pathology. Nose Neoplasms / diagnosis
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Maxillary Sinus Neoplasms / diagnosis. Neoplasm Recurrence, Local / pathology. Orbital Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Am J Clin Oncol. 1990 Apr;13(2):139-43 [2180272.001]
  • [Cites] Arch Otolaryngol. 1979 Jul;105(7):427-30 [454301.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Jun;15(6):1169-77 [8073990.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):73-8 [7712654.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jan;123(1):34-40 [9006501.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15221218.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Sinnott BP, Hatipoglu B, Sarne DH: Intrasellar plasmacytoma presenting as a non-functional invasive pituitary macro-adenoma: case report & literature review. Pituitary; 2006;9(1):65-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 57 year old woman was referred to our department with a presumed diagnosis of a non-functioning pituitary macro-adenoma.
  • She reported a 3 month history of headaches and a 2 week history of sudden onset of right facial numbness.
  • A diagnosis of multiple myeloma was made 1 month later based on a combination of clinical, pathological and radiologic features.
  • She underwent radiation therapy directed towards the residual sellar tumor, followed by chemotherapy and autologous stem cell transplantation.
  • Review of the world literature revealed only 22 previous reports of patients in whom a solitary plasmacytoma or multiple myeloma first presented as a sellar mass; in all cases mimicking clinically and radiologically a non-functioning invasive pituitary adenoma however with additional cranial nerve involvement.
  • Intrasellar plasma cell tumors are rare tumors which may mimic non-functioning invasive pituitary tumors.
  • The diagnosis should be suspected in patients with well preserved anterior pituitary function and cranial nerve neuropathies in the presence of significant sellar destruction.
  • [MeSH-major] Adenoma / diagnosis. Pituitary Neoplasms / diagnosis. Plasmacytoma / diagnosis. Plasmacytoma / surgery
  • [MeSH-minor] Deamino Arginine Vasopressin / therapeutic use. Diabetes Insipidus / drug therapy. Diabetes Insipidus / etiology. Diagnosis, Differential. Female. Humans. Middle Aged. Postoperative Complications. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):653-4 [3558056.001]
  • [Cites] Br J Neurosurg. 2003 Jun;17(3):260-2 [14565527.001]
  • [Cites] Surg Neurol. 1992 May;37(5):388-93 [1631767.001]
  • [Cites] Arch Neurol. 1982 Nov;39(11):738 [7126006.001]
  • [Cites] Brain. 1954;77(1):61-81 [13160259.001]
  • [Cites] Tumori. 2001 Nov-Dec;87(6):451-4 [11989605.001]
  • [Cites] Comput Radiol. 1986 Jul-Aug;10(4):201-5 [3791987.001]
  • [Cites] Med Clin (Barc). 1982 Nov 1-15;79(8):377-9 [6816996.001]
  • [Cites] Arch Neurol. 1963 Nov;9:534-44 [14057685.001]
  • [Cites] J Clin Neurosci. 2002 Sep;9(5):586-9 [12383423.001]
  • [Cites] Lancet. 1967 Dec 23;2(7530):1354-6 [4170040.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):218-21 [7616264.001]
  • [Cites] Postgrad Med J. 1985 Jun;61(716):513-4 [4011536.001]
  • [Cites] Cancer. 1979 Apr;43(4):1513-5 [445346.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):55-6 [576202.001]
  • [Cites] Surg Neurol. 1980 Sep;14(3):233-6 [7001658.001]
  • [Cites] Bull Soc Ophtalmol Fr. 1981 Mar;81(3):355-6 [7226412.001]
  • [Cites] Pathol Oncol Res. 2003;9(2):134-7 [12858221.001]
  • [Cites] Australas Radiol. 2001 May;45(2):244-6 [11380375.001]
  • [Cites] Exp Clin Endocrinol. 1993;101(5):283-9 [8299704.001]
  • [Cites] J Neuroophthalmol. 1996 Sep;16(3):199-203 [8865015.001]
  • [Cites] Arch Neurol. 1992 May;49(5):555-8 [1580820.001]
  • [Cites] Endocr Pract. 1998 Nov-Dec;4(6):382-6 [15251713.001]
  • [Cites] Ital J Neurol Sci. 1994 Oct;15(7):369-72 [7698896.001]
  • [Cites] Rinsho Ketsueki. 1996 Mar;37(3):260-4 [8727353.001]
  • [Cites] Neurol Neurochir Pol. 1991 Sep-Oct;25(5):683-8 [1808532.001]
  • [Cites] Neurochirurgie. 1991;37(1):67-71 [2017297.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Aug;47(4):230-4 [15346320.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Jan;47(1):99-100 [6693924.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3455-9 [8855784.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2637-45 [15602025.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1201-3 [9298068.001]
  • [Cites] Pituitary. 2004;7(3):179-181 [16328566.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(2):219-20 [10189508.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1513-7 [1540888.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Br J Neurosurg. 1991;5(4):405-7 [1786137.001]
  • [Cites] No Shinkei Geka. 2001 Jun;29(6):551-7 [11452502.001]
  • (PMID = 16703411.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] ENR1LLB0FP / Deamino Arginine Vasopressin
  • [Number-of-references] 42
  •  go-up   go-down


17. Karatas Silistreli O, Ayhan M, Görgü M, Oztan Y, Sisman N: A primitive neuroectodermal tumor on the face: case report. Acta Chir Plast; 2005;47(2):38-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A primitive neuroectodermal tumor on the face: case report.
  • In 1918, Stout defined the lesion in which small round cells originating from the ulnar nerve formed a rosette as neuroepithelioma.
  • It was claimed that this tumor originated from neuroectodermis and was different from the classical neuroblastoma.
  • The term primitive neuroectodermal tumor (PNET) involves a group of tumors of the soft tissue originating from neural crest and resulting from the brain, spinal cord and branches of the sympathetic nervous system.
  • Extracranial primitive neuroectodermal tumors originate from neural crest cells outside the sympathetic and central nervous system.
  • It is usually encountered in children and young adults; most frequently located in thoracopulmonary region (Askin's tumor).
  • PNET is an aggressive tumor.
  • It is treated with aggressive surgery as well as chemotherapy and radiotherapy.
  • Clinicians should be on alert when treating facial tumors, not to skip PNET, which is a very aggressive one.
  • [MeSH-major] Facial Neoplasms / surgery. Neuroectodermal Tumors / surgery
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Cheek. Humans. Lung Neoplasms / secondary. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033149.001).
  • [ISSN] 0001-5423
  • [Journal-full-title] Acta chirurgiae plasticae
  • [ISO-abbreviation] Acta Chir Plast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


18. Stannard C, Sealy R, Hering E, Hough J, Knowles R, Lecuona K, Reddi VB: Postenucleation orbits in retinoblastoma: treatment with 125I brachytherapy. Int J Radiat Oncol Biol Phys; 2002 Dec 1;54(5):1446-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postenucleation orbits in retinoblastoma: treatment with 125I brachytherapy.
  • PURPOSE: Children with retinoblastoma that extends into or through the choroid, sclera, or optic nerve are at risk of developing orbital disease, as well as metastases.
  • Previously, these enucleated orbits were treated with external beam radiotherapy in addition to chemotherapy.
  • 125I brachytherapy for tumors in and around the eye was pioneered by Sealy in Cape Town, South Africa, in 1974.
  • In 1983, he developed a technique to irradiate the contents of the orbit while limiting the dose to the bony orbit and eyelids.
  • A seventh unscreened tube was placed in the center, and a metal disc with 125I seeds on its posterior surface was secured beneath the eyelids.
  • Thirty-six were treated prophylactically and 21, with tumor at the resection line of the nerve, extrascleral tumor, or metastases, were treated therapeutically.
  • They received a median dose of 34 Gy in 70 h; 30 also received chemotherapy.
  • Children with tumor at the resection line of the nerve also received treatment to the craniospinal axis.
  • Eight of the 13 patients with microscopic extraocular tumor survived a median of 29 months (range 5-156).
  • None of the 8 patients presenting with orbital tumor or metastases survived.
  • No orbital recurrences developed in any of the patients.
  • CONCLUSION: Orbital brachytherapy is an effective method of irradiating the orbit to prevent recurrent tumor, the treatment time is short, and the cosmesis is much more acceptable than with other forms of irradiation.
  • No facial atrophy or second nonocular tumors have occurred.
  • [MeSH-major] Brachytherapy / instrumentation. Brachytherapy / methods. Eye Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Retinoblastoma / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Dose-Response Relationship, Radiation. Follow-Up Studies. Hot Temperature. Humans. Infant. Neoplasm Metastasis. Radiometry. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12459368.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes
  •  go-up   go-down


19. Esposito F, Kelly DF, Vinters HV, DeSalles AA, Sercarz J, Gorgulhos AA: Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies. J Neurooncol; 2006 Feb;76(3):299-306
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies.
  • BACKGROUND: Primary neoplasms of the sphenoid sinus are a rare occurrence, accounting for approximately 1-2% of all paranasal sinus tumors.
  • METHODS: Four patients with sphenoid sinus neoplasms were identified (1%), all treated during the year 2003.
  • Two patients presented with unilateral abducens cranial nerve (CN) palsies; one had trigeminal facial numbness and dizziness; another had headache, epistaxis, and partial third and fourth CN palsies.
  • Cavernous sinus invasion was present in all four cases, including one patient with tumor in the ethmoid sinus and intra-tumoral hemorrhage.
  • All patients underwent subtotal tumor removal via an endonasal transsphenoidal route.
  • Tumor histology included neuroendocrine carcinoma, sinonasal undifferentiated carcinoma, mucoepidermoid carcinoma, and giant cell tumor.
  • Metastatic work-ups were negative in all patients, and all received fractionated stereotactic radiotherapy; three received chemotherapy.
  • One patient required a second endonasal tumor debulking 15 months after the first for new visual loss that then resolved.
  • CONCLUSIONS: Intra-sphenoidal tumors are locally invasive tumors that include a wide pathological spectrum.
  • Recognizing their distinctive clinical presentation and MRI features is helpful in differentiating them from primary sellar tumors.
  • Their aggressive nature warrants a multimodality treatment plan including surgical debulking, radiotherapy, and chemotherapy in some cases.
  • [MeSH-major] Neurosurgical Procedures. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy. Sphenoid Sinus / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma / therapy. Carcinoma, Giant Cell / metabolism. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / therapy. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2002 Sep;51(3):699-705; discussion 705-7 [12188948.001]
  • [Cites] Head Neck Surg. 1984 Jan-Feb;6(3):761-76 [6319335.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Laryngoscope. 1989 Jul;99(7 Pt 1):716-20 [2747395.001]
  • [Cites] Laryngoscope. 1963 May;73:537-46 [14011951.001]
  • [Cites] Cephalalgia. 1988 Dec;8(4):229-36 [3219724.001]
  • [Cites] Laryngoscope. 1997 Dec;107(12 Pt 1):1590-5 [9396670.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14 (1):11-22 [3335447.001]
  • [Cites] Yonsei Med J. 1988;29(3):209-18 [3057747.001]
  • [Cites] Head Neck. 1996 Mar-Apr;18(2):160-5; discussion 166 [8647682.001]
  • [Cites] Neurosurgery. 1993 Oct;33(4):602-8; discussion 608-9 [8232799.001]
  • [Cites] J Neurosurg. 1981 Aug;55(2):187-93 [7252541.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Laryngoscope. 1973 Aug;83(8):1252-65 [4758128.001]
  • [Cites] Pituitary. 2002;5(4):261-5 [14558675.001]
  • [Cites] World J Surg. 2003 Jul;27(7):849-55 [14509518.001]
  • [Cites] Minim Invasive Neurosurg. 1998 Jun;41(2):66-73 [9651913.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):663-72 [12152781.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):581-9 [1503031.001]
  • [Cites] J Otolaryngol. 1978 Oct;7(5):379-88 [105151.001]
  • [Cites] Arch Otolaryngol. 1978 Oct;104(10):585-7 [697636.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):765-8 [8663951.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1084-91; discussion 1091-2 [10807240.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Jun;102(6):709-16 [2115658.001]
  • [Cites] Eur J Pediatr. 1996 Aug;155(8):717-9 [8839732.001]
  • [Cites] J Otolaryngol. 1990 Apr;19(2):122-9 [2348505.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Head Neck. 1991 May-Jun;13(3):208-12 [2037472.001]
  • [Cites] Med J Aust. 2000 Nov 20;173(10):548-9 [11194741.001]
  • [Cites] Neuroradiology. 1998 Oct;40(10 ):651-5 [9833894.001]
  • [Cites] Brain. 1984 Sep;107 ( Pt 3):855-70 [6478180.001]
  • [Cites] J Craniofac Surg. 1995 Jan;6(1):15-23 [8601000.001]
  • [Cites] J Neurosurg Sci. 1999 Mar;43(1):25-36 [10494663.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Br J Neurosurg. 1994;8(1):51-5 [8011194.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 May;259(5):266-8 [12107531.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):350-8 [12593622.001]
  • [Cites] Pathology (Phila). 1996;3(2):513-34 [8795833.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Jan;120(1):19-25 [8274251.001]
  • [Cites] Am J Emerg Med. 2001 Jan;19(1):88-90 [11146033.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):913-5; discussion 915-6 [9574657.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):367-72 [12598339.001]
  • [Cites] Neurosurgery. 2003 Nov;53(5):1126-35; discussion 1135-7 [14580279.001]
  • [Cites] Cancer. 1977 Dec;40(6):3038-41 [412586.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] J Laryngol Otol. 1995 Oct;109(10):951-5 [7499947.001]
  • (PMID = 16163447.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Benoliel R, Epstein J, Eliav E, Jurevic R, Elad S: Orofacial pain in cancer: part I--mechanisms. J Dent Res; 2007 Jun;86(6):491-505
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mechanisms involved, and possible treatment targets, in orofacial pain due to cancer are poorly understood.
  • In the second part, we review the clinical presentation of cancer-associated orofacial pain at various stages: initial diagnosis, during therapy (chemo-, radiotherapy, surgery), and in the post-therapy period.
  • Tissue destruction by invasive tumors (or metastases) induces inflammation and nerve damage, with attendant acute pain.
  • Distant, painful effects of tumors include paraneoplastic neuropathic syndromes and effects secondary to the release of factors by the tumor (growth factors, cytokines, and enzymes).
  • Additionally, pain is frequent in cancer management protocols (surgery, chemotherapy, and radiotherapy).
  • [MeSH-major] Facial Pain / etiology. Head and Neck Neoplasms / complications
  • [MeSH-minor] Animals. Chronic Disease. Disease Models, Animal. Humans. Pain, Referred / etiology. Pain, Referred / physiopathology. Paraneoplastic Syndromes / etiology. Paraneoplastic Syndromes / physiopathology. Trigeminal Nerve / physiopathology. Trigeminal Neuralgia / etiology. Trigeminal Neuralgia / physiopathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525348.001).
  • [ISSN] 0022-0345
  • [Journal-full-title] Journal of dental research
  • [ISO-abbreviation] J. Dent. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 242
  •  go-up   go-down


21. Numata T, Hiruma K, Tsukuda T, Asano T: [Malignant mixed tumor]. Gan To Kagaku Ryoho; 2004 Mar;31(3):314-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant mixed tumor].
  • The term "malignant mixed tumor" is usually synonymous with "carcinoma in pleomorphic adenoma," a secondary carcinoma developing in pre-existing pleomorphic adenoma.
  • However, it sometimes indicates a group of tumors consisting of carcinoma in pleomorphic adenoma, carcinosarcoma (true malignant mixed tumor) and metastasizing benign mixed tumor, the latter 2 being the most infrequent.
  • The main type of carcinomas arising in pleomorphic adenoma were undifferentiated carcinoma, adenocarcinoma and squamous cell carcinoma.
  • The treatment of choice for carcinoma in pleomorphic adenoma has consisted of en-bloc excision with wide margin.
  • Invasive growth, facial nerve involvement, lymph node metastasis or high-grade malignant tumor are grounds for postoperative radiation therapy.
  • The role of chemotherapy has not yet been well established.
  • [MeSH-major] Mixed Tumor, Malignant. Salivary Gland Neoplasms
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Carcinosarcoma / diagnosis. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045931.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Rittinger O, Kranzinger M, Jones R, Jones N: Malignant astrocytoma arising 10 years after combined treatment of craniopharyngioma. J Pediatr Endocrinol Metab; 2003 Jan;16(1):97-101
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant astrocytoma arising 10 years after combined treatment of craniopharyngioma.
  • Craniopharyngioma is the third most common intracranial tumor in childhood.
  • Following surgery, virtually all patients present with hypopituitarism and are at considerable risk of tumor recurrence.
  • Secondary tumors, however, are rare, occurring usually 10 years after diagnosis and associated with poor prognosis.
  • After surgery he underwent conventional radiation therapy with a total tumor dose of 55 Gy, and had hormonal support with DDAVP, thyroxine, and a variable dose of hydrocortisone.
  • Growth velocity declined slowly in the first 4 years, but improved later on again without GH therapy despite abnormal provocative tests.
  • At the age of 15 years he developed peripheral facial nerve palsy due to a malignant astrocytoma (WHO grade III/IV).
  • Repeated conventional radiation therapy with an additional stereotactic boost and chemotherapy could not prevent the fatal outcome.
  • This observation may temper the use of radiosurgery in benign intracranial tumors.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Stem Neoplasms / diagnosis. Craniopharyngioma / radiotherapy. Craniopharyngioma / surgery. Neoplasms, Second Primary / diagnosis. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Fatal Outcome. Hormones / blood. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Time Factors

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12585346.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hormones
  •  go-up   go-down


23. Schouten-van Meeteren AY, van der Valk P, van der Linden HC, Moll AC, Imhof SM, Huismans DR, Loonen AH, Veerman AJ: Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay. Cancer; 2001 Dec 1;92(11):2933-40
Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay.
  • BACKGROUND: Retinoblastoma is frequently treated with chemotherapy to facilitate intraocular therapy, as well as to diminish or delay radiotherapy in invasive disease.
  • Radiotherapy is effective in ocular retinoblastoma, but is associated with facial deformation and a higher chance for second primary tumors in the irradiation field.
  • These sequelae emphasize the need to determine more effective chemotherapy schedules and local treatment.
  • The aim of this study is to investigate the relation between in vitro drug resistance for ten cytostatic drugs and histopathologic features in primary retinoblastoma.
  • Forty-four fresh samples of primary retinoblastoma were tested for in vitro drug resistance using the 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide (MTT) assay.
  • RESULTS: The differentiation of the tumors revealed 24 poorly differentiated, 14 intermediately differentiated, and 6 well differentiated tumors.
  • Tumor infiltration showed 3 minimal and 3 massive choroideal invasions, as well as 21 prelaminary and 2 postlaminary optic nerve invasions.
  • The tumor was unifocal in 16 eyes and multifocal in 28 eyes, with extensive retinal involvement in 10 eyes and tumor seeding in 21 eyes.
  • The MTT assay was successful in 82% of the samples after enzymatic handling of the tumor cells was omitted.
  • Undifferentiated tumors were more sensitive to carboplatin (p = 0.034) and doxorubicin (p = 0.025), thiotepa (p = 0.051) and ifosfamide (p = 0.075) in comparison to differentiated tumors.
  • Type of retinal involvement, invasion, focality, and seeding did not show a relationship with drug resistance.
  • Calcified tumors were more resistant to actinomycin D and ifosfamide and more sensitive to vincristine; conversely, apoptotic tumors were more sensitive to ifosfamide and more resistant to vincristine (p = 0.027).
  • Necrotic tumors were more sensitive to actinomycin D (p = 0.004), and mitotic tumors were more sensitive to idarubicin (p = 0.026).
  • In 90% of the tumors extreme drug resistance to cytarabin was present.
  • CONCLUSIONS: In retinoblastoma many histopathologic features are related to in vitro drug resistance.
  • Undifferentiated tumors are more sensitive to several cytostatic drugs.
  • Calcification and apoptosis show an inverse relation with in vitro drug resistance to ifosfamide and vincristine.
  • Extreme drug resistance to cytarabin is observed; this drug should not be used in retinoblastoma treatment.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Resistance / physiology. Retinoblastoma / pathology. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Cell Differentiation. Cell Size / drug effects. Cytarabine / pharmacology. Drug Screening Assays, Antitumor. Humans

  • Genetic Alliance. consumer health - Retinoblastoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11753969.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tetrazolium Salts; 0 / Thiazoles; 04079A1RDZ / Cytarabine; 298-93-1 / thiazolyl blue
  •  go-up   go-down


24. Daya H, Chan HS, Sirkin W, Forte V: Pediatric rhabdomyosarcoma of the head and neck: is there a place for surgical management? Arch Otolaryngol Head Neck Surg; 2000 Apr;126(4):468-72
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To review and evaluate the place of surgical treatment in the management of rhabdomyosarcoma of the head and neck in children.
  • INTERVENTIONS: Surgery, chemotherapy, and radiotherapy.
  • MAIN OUTCOME MEASURES: Disease-free survival and long-term morbidity from treatment.
  • RESULTS: Twenty patients had parameningeal and 9 had nonparameningeal head and neck tumors.
  • All were treated with chemotherapy.
  • Eleven patients underwent surgery as definitive therapy.
  • Using the Intergroup Rhabdomyosarcoma Study (IRS) staging system, 5 of these 11 patients had complete resection of tumor (IRS group I) and avoided radiotherapy.
  • The other 6 patients required radiation because of compromised, regional, or incomplete resection of tumor.
  • Three had incomplete resections with gross residual tumor (IRS group III).
  • Long-term surgical morbidity was seen in 36% (4/11) of the patients and included facial nerve paralysis, trismus, and cosmetic deformity.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Rhabdomyosarcoma, Alveolar / surgery. Rhabdomyosarcoma, Embryonal / surgery
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Postoperative Complications / epidemiology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10772299.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


25. Leach BC, Kulbersh JS, Day TA, Cook J: Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer. Dermatol Surg; 2008 Apr;34(4):483-97
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer.
  • OBJECTIVE: The purpose of this study was to identify and characterize recurrent skin cancers of the head and neck presenting with cranial neuropathies and to review the presentation and the management for this rare subset of cutaneous neoplasms.
  • MATERIALS AND METHODS: A retrospective review was performed for all patients with previous related cutaneous neoplasms presenting with cranial neuropathies referred to a single academic tertiary-care head and neck tumor program from 1999 to 2007.
  • Six cases of head and neck carcinoma with demonstrable cranial neuropathy were identified and analyzed by clinical history, radiographic and surgical findings, and treatment and survival data.
  • RESULTS: Cranial neuropathy was the presenting symptom of recurrent disease in all six patients.
  • Four presented with multiple cranial neuropathies.
  • All exhibited neuropathy of the trigeminal nerve (cranial nerve V).
  • The tumors involved were squamous cell carcinoma (4) and melanoma (2).
  • All patients were multiply symptomatic, presenting with a mean of three neurologic symptoms, including facial numbness (5), facial paralysis or weakness (3), facial pain (3), diplopia (3), paresthesia (3), hearing loss (1), or formication (2).
  • Symptoms were present for an average of 7 months prior to diagnosis of perineural recurrence.
  • Cranial nerve involvement was confirmed in all patients by magnetic resonance imaging, and five patients manifested histologic evidence of perineural tumor infiltration.
  • Treatment consisted of various combinations of surgery, radiation, and chemotherapy for five patients, and one patient declined any intervention.
  • CONCLUSION: Cranial neuropathy is a rare presentation of recurrent cutaneous neoplasms of the head and neck.
  • Given this infrequent occurrence and shared features of presentation, these highly morbid tumors are often mistakenly diagnosed as Bell's palsy or trigeminal neuralgia.
  • Our findings corroborate previous reports of diagnostic delay, increased tumor burden, and worsened morbidity and mortality associated with such cutaneous malignancies.
  • The critical utility of radiologic imaging for staging and tumor delineation are also supported by our institutional data.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cranial Nerve Diseases / etiology. Head and Neck Neoplasms / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Cohort Studies. Humans. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248467.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Varma AK, Muller PJ: Cranial neuropathies after intracranial Photofrin-photodynamic therapy for malignant supratentorial gliomas-a report on 3 cases. Surg Neurol; 2008 Aug;70(2):190-3
MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial neuropathies after intracranial Photofrin-photodynamic therapy for malignant supratentorial gliomas-a report on 3 cases.
  • BACKGROUND: In an RCT of PDT in the treatment of malignant gliomas, 3 patients developed cranial neuropathies after photoillumination.
  • We are aware of no previous reports on cranial neuropathy after intracranial PDT.
  • METHODS: In a cohort of 80 patients, there were 41 men and 39 women; 47 were newly diagnosed and 33 had recurrent tumors.
  • All patients underwent surgical tumor extirpation.
  • There were 77 malignant gliomas, 2 meningiomas, and 1 metastatic tumor.
  • The tumor locations were as follows: 39 frontal, 25 temporal, 12 parietal, and 4 occipital.
  • Of the 25 patients with temporal lobe tumors, 18 received PDT.
  • RESULTS: Three of the 18 patients with temporal lobe tumors developed cranial neuropathies after PDT.
  • This complication was not seen in any other patient with tumors in the frontal, parietal, or occipital regions, or patients with temporal lobe tumors who did not receive PDT.
  • The first patient developed seventh nerve paresis and hypoesthesia in fifth nerve distribution, which resolved only partially.
  • The second patient developed a seventh nerve paresis that resolved completely.
  • The third patient developed transient neuralgic pain in the trigeminal nerve distribution.
  • CONCLUSIONS: Cranial neuropathies could be the result of photoillumination of fifth and seventh cranial nerves during PDT of the temporal fossa.
  • [MeSH-major] Cranial Nerve Diseases / chemically induced. Dihematoporphyrin Ether / adverse effects. Glioma / drug therapy. Peripheral Nervous System Diseases / chemically induced. Photochemotherapy / adverse effects. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / adverse effects. Cranial Fossa, Middle / pathology. Facial Nerve / anatomy & histology. Facial Nerve / drug effects. Facial Nerve / physiopathology. Facial Nerve Diseases / chemically induced. Facial Nerve Diseases / metabolism. Facial Nerve Diseases / physiopathology. Female. Humans. Light / adverse effects. Male. Middle Aged. Photic Stimulation / adverse effects. Preoperative Care / standards. Temporal Lobe / pathology. Temporal Lobe / physiopathology. Trigeminal Nerve / anatomy & histology. Trigeminal Nerve / drug effects. Trigeminal Nerve / physiopathology. Trigeminal Nerve Diseases / chemically induced. Trigeminal Nerve Diseases / metabolism. Trigeminal Nerve Diseases / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976702.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


27. Landström FJ, Nilsson CO, Crafoord S, Reizenstein JA, Adamsson GB, Löfgren LA: Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg; 2010 Aug;36(8):1245-50
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electroporation therapy of skin cancer in the head and neck area.
  • BACKGROUND: Electroporation therapy is a new cancer treatment modality in which a locally applied electrical field enhances cell membrane permeability, allowing greater intracellular accumulation of a chemotherapeutic agent.
  • OBJECTIVE: To evaluate the efficacy of electroporation therapy in treating basal cell and squamous cell carcinomas of the skin.
  • MATERIALS AND METHODS: Six patients with skin cancer of the head and neck were treated using electroporation therapy with intratumorally injected bleomycin.
  • Orbital growth, facial nerve proximity, or proximity to cartilage of the external meatus complicated four of these tumors.
  • RESULTS: In four of the six patients, one treatment was enough to eradicate the tumor.
  • In one patient, the tumor persisted even after a second treatment with electroporation therapy.
  • One additional recurrence was recorded 6 months after the follow-up period CONCLUSION: Electroporation therapy is a promising new cancer treatment that should be further evaluated as an alternative to surgery, especially in complicated skin cancer.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Electrochemotherapy. Head and Neck Neoplasms / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Ear Neoplasms / drug therapy. Female. Humans. Male. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2011 Feb;37(2):286; author reply 287 [21324036.001]
  • (PMID = 20666812.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


28. Meziane M, Boulaadas M, Eabdenbitsen A, Dib N, Essakalli L, Kzadri M: [Intramasseteric hemangioma operated by intraoral approach]. Rev Stomatol Chir Maxillofac; 2010 Jun;111(3):168-71
Hazardous Substances Data Bank. DIATRIZOATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hémangiome du masséter opéré par voie intra-orale.
  • INTRODUCTION: Hemangiomas are benign vascular tumors, of unknown origin.
  • In this case, treatment is usually surgery via an extra-oral approach which imposes parotidectomy with dissection of facial nerve branches.
  • DISCUSSION: Intraoral intramasseteric hemangioma exeresis is possible and does not seem to lead to more complications than with the facial approach.
  • It prevents the significant drawbacks due to cutaneous incision, parotidectomy, and dissection of facial nerve branches via a facial approach.
  • [MeSH-major] Hemangioma / diagnosis. Masseter Muscle / pathology. Muscle Neoplasms / diagnosis
  • [MeSH-minor] Adult. Angiography. Combined Modality Therapy. Diatrizoate / therapeutic use. Drug Combinations. Embolization, Therapeutic. Fatty Acids / therapeutic use. Follow-Up Studies. Humans. Male. Oral Surgical Procedures / methods. Propylene Glycols / therapeutic use. Sclerosing Solutions / therapeutic use. Tomography, X-Ray Computed. Zein / therapeutic use

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20553891.001).
  • [ISSN] 1776-257X
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Fatty Acids; 0 / Propylene Glycols; 0 / Sclerosing Solutions; 117-96-4 / Diatrizoate; 9010-66-6 / Zein; 91196-33-7 / alcoholic prolamine solution
  •  go-up   go-down


29. Tankéré F, Bernat I: [Bell's palsy: from viral aetiology to diagnostic reality]. Rev Med Interne; 2009 Sep;30(9):769-75
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peripheral injury of the facial nerve is a frequent disorder.
  • Facial palsy is due to a lesion involving the facial pontine nucleus or the nerve trunk in its route from the pontocerebellar angle to the parotid.
  • The idiopathic facial paralysis or Bell's palsy (BP) is the most common cause but acute facial palsy can also be due to tumors.
  • A rigorous clinical history and examination must be performed to guide the additional biological, radiological and cochleovestibular investigations in order to reach the diagnosis.
  • The pathophysiology of BP remains unclear, but seems to be due to the reactivation of Herpes simplex virus type 1 within the intrapetrous pathway of facial nerve.
  • The treatment remains controversial but, for most of the authors, consists of early administration of corticosteroids with or without antiviral agents.
  • Ninety percent of the patients recover normal facial function with this treatment.
  • They need appropriate rehabilitation and for some authors facial nerve surgical decompression in emergency.

  • Genetic Alliance. consumer health - Bell's Palsy.
  • MedlinePlus Health Information. consumer health - Bell's Palsy.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19195745.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; 0 / Antiviral Agents; 0 / Glucocorticoids; VB0R961HZT / Prednisone; X4HES1O11F / Acyclovir
  • [Number-of-references] 44
  •  go-up   go-down


30. Rutigliano DN, Meyers P, Ghossein RA, Carlson DL, Kayton ML, Kraus D, La Quaglia MP: Mucoepidermoid carcinoma as a secondary malignancy in pediatric sarcoma. J Pediatr Surg; 2007 Jul;42(7):E9-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Children diagnosed with osteosarcoma (OS) and Ewing sarcoma (ES) have greatly benefited from the addition of alkylator therapy.
  • However, with greater numbers of long-term survivors, the rising incidence of secondary malignant neoplasms (SMNs) is concerning.
  • Herein we report on 2 patients with sarcoma who developed a case of secondary mucoepidermoid carcinoma after chemotherapy treatment without associated radiation therapy.
  • Details of their initial evaluation, previous therapies, resection techniques, pathologic findings, and follow-up compose this report.
  • Both patients underwent primary resection and chemotherapy including alkylating agents, but neither received radiation.
  • The mucoepidermoid carcinomas developed 27 months and 132 months after completion of therapy, respectively, and were noted on routine yearly follow-up.
  • Fine-needle aspiration was nondiagnostic on each, and parotidectomy with preservation of the facial nerve was performed.
  • Pathology revealed low-grade mucoepidermoid carcinoma with tumor extending to the deep margins for both lesions, and radiotherapy to the parotid bed was administered.
  • CONCLUSION: Primary mucoepidermoid carcinoma of the parotid gland accounts for less than 10% of all head and neck tumors in childhood.
  • This is the first reported series of parotid mucoepidermoid carcinomas occurring after sarcoma treatment without radiotherapy.
  • A common link between the 2 patients may be the use of alkylating therapy.
  • [MeSH-major] Bone Neoplasms / pathology. Carcinoma, Mucoepidermoid / pathology. Neoplasms, Second Primary / pathology. Osteosarcoma / pathology. Parotid Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Female. Humans. Male

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618873.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement